Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budget

Enlarge / Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Biogen Inc. shares soared after its controversial Alzheimer’s disease therapy was approved by US regulators. (credit: Getty | Bloomberg) Concern is mounting over the price of the controversial new Alzheimer’s drug Aduhelm. Advocates, lawmakers, Continue Reading